GLP-1 Weight Loss Timeline: Realistic Results Month by Month

Patients starting GLP-1 therapy often ask the same question: "When will I see results?" The answer varies, but clinical trial data gives us a realistic timeline. This article walks through what to expect at each stage, based on the STEP (Wegovy) and SURMOUNT (Zepbound/Mounjaro) clinical trial datasets.

Weeks 1-4: Onboarding

Most prescribers start GLP-1 at a low dose (0.25mg Wegovy / 2.5mg Zepbound) and titrate up monthly. Early weight loss in this phase is typically modest — 2-5 lbs is common. The primary purpose of this phase is tolerance, not rapid weight loss.

• Expect mild appetite reduction within 1-2 weeks
• Common side effects: nausea, mild GI upset (usually resolve within 1-2 weeks)
• Average weight loss week 4: ~2.5 lbs

Weeks 4-12: Steady progress

Dose typically increases over weeks 4-12. Appetite suppression and reduced food noise become more pronounced. Weight loss accelerates.

• Average cumulative loss by week 12: ~5-7% of starting body weight
• For a 200 lb person, ~10-14 lbs
• Side effects often stabilize or improve
• Many patients report needing significantly smaller portions

Weeks 12-24: Approaching maintenance dose

By week 16-20, most patients have reached or are approaching the target maintenance dose (2.4mg Wegovy, 15mg Zepbound for those who tolerate). This is where weight loss is fastest for most.

• Average cumulative loss by week 24: ~10-12% (Wegovy), ~12-15% (Zepbound)
• For a 200 lb person, ~20-30 lbs
• Energy levels often improve
• Cardiovascular markers (blood pressure, lipids) typically improve in parallel

Weeks 24-48: Plateau and stabilization

Weight loss continues but at a slower rate. The body adapts metabolically; this is normal physiology.

• Average cumulative loss by week 48: ~14-15% (Wegovy STEP-1), ~20-22.5% (Zepbound SURMOUNT-1)
• Body composition continues to improve
• Many patients report normalized hunger cues

Beyond week 48: Maintenance

After approximately 12-18 months, weight loss plateaus for most patients. The medication continues to provide appetite suppression and metabolic benefit, but the body has reached a new homeostasis.

Clinical trial data shows that stopping GLP-1 medication typically leads to weight regain — most patients regain 50-70% of lost weight within 12 months of discontinuation. For sustained benefit, most current guidelines recommend continued maintenance therapy.

What if I am not seeing these results?

Individual response varies significantly. Approximately 15-20% of patients are "non-responders" — they do not achieve >5% weight loss at maintenance dose. If you are at maintenance dose and have not seen meaningful progress by week 24, discuss with your prescriber:

• Are you taking the medication as prescribed?
• Is calorie intake supporting weight loss?
• Are you getting adequate protein and exercise?
• Would switching to a different GLP-1 (e.g., Wegovy → Zepbound) help?

Bottom line

Realistic GLP-1 weight loss is gradual: 2-5 lbs in month 1, 10-14 lbs by month 3, 20-30 lbs by month 6, and 30-40+ lbs by month 12 for most patients on Zepbound. Wegovy results are typically 25-30% less. Individual results vary, and these are averages — your trajectory may differ.